Somewhat Positive Media Coverage Extremely Likely to Impact Baxter International (BAX) Stock Price

Media headlines about Baxter International (NYSE:BAX) have trended somewhat positive this week, InfoTrie reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Baxter International earned a news impact score of 1.17 on their scale. InfoTrie also gave news stories about the medical instruments supplier an news buzz score of 10 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock’s share price in the immediate future.

Here are some of the news stories that may have impacted Baxter International’s analysis:

Shares of Baxter International stock opened at $65.47 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.60 and a quick ratio of 1.96. The company has a market capitalization of $34.87 billion, a P/E ratio of 26.40, a P/E/G ratio of 1.76 and a beta of 1.02. Baxter International has a fifty-two week low of $61.05 and a fifty-two week high of $78.38.

Baxter International (NYSE:BAX) last released its earnings results on Wednesday, October 31st. The medical instruments supplier reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.06. Baxter International had a net margin of 10.90% and a return on equity of 17.67%. The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.79 billion. During the same quarter in the previous year, the business earned $0.64 EPS. The business’s quarterly revenue was up 2.2% compared to the same quarter last year. Equities analysts predict that Baxter International will post 3 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 2nd. Shareholders of record on Monday, December 3rd will be issued a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a yield of 1.16%. The ex-dividend date of this dividend is Friday, November 30th. Baxter International’s dividend payout ratio is presently 30.65%.

Baxter International announced that its board has approved a share repurchase program on Tuesday, November 13th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical instruments supplier to reacquire up to 6.1% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its shares are undervalued.

BAX has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Baxter International from a “hold” rating to a “buy” rating and set a $87.00 price objective for the company in a report on Tuesday, September 25th. Argus reissued a “hold” rating on shares of Baxter International in a report on Tuesday, September 4th. Morgan Stanley raised their price target on shares of Baxter International from $68.00 to $75.00 and gave the company an “underweight” rating in a report on Thursday, October 11th. Royal Bank of Canada lowered their price target on shares of Baxter International from $76.00 to $70.00 and set a “sector perform” rating for the company in a report on Thursday, November 8th. Finally, Barclays started coverage on shares of Baxter International in a report on Monday, October 15th. They issued an “underweight” rating and a $73.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and eleven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $73.81.

In other Baxter International news, SVP Giuseppe Accogli sold 17,647 shares of Baxter International stock in a transaction on Monday, September 17th. The shares were sold at an average price of $77.27, for a total transaction of $1,363,583.69. Following the completion of the sale, the senior vice president now owns 59,452 shares of the company’s stock, valued at approximately $4,593,856.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.05% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by WKRB News and is the sole property of of WKRB News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at

About Baxter International

Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Featured Story: Cost of equity and a company’s balance sheet

Insider Buying and Selling by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with's FREE daily email newsletter.

Leave a Reply